BB&T Securities LLC increased its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 15.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 564,006 shares of the biopharmaceutical company’s stock after buying an additional 74,503 shares during the period. BB&T Securities LLC’s holdings in Bristol-Myers Squibb were worth $35,949,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Tradewinds Capital Management LLC boosted its stake in Bristol-Myers Squibb by 34.6% in the 2nd quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 500 shares in the last quarter. Atlantic Trust LLC acquired a new stake in Bristol-Myers Squibb during the 2nd quarter valued at approximately $111,000. Massey Quick Simon & CO. LLC lifted its stake in Bristol-Myers Squibb by 523.5% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after acquiring an additional 1,492 shares during the period. Blue Chip Partners Inc. lifted its stake in Bristol-Myers Squibb by 0.7% during the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after acquiring an additional 15 shares during the period. Finally, Horan Capital Advisors LLC. acquired a new stake in Bristol-Myers Squibb during the 3rd quarter valued at approximately $122,000. 69.56% of the stock is currently owned by institutional investors and hedge funds.
Bristol-Myers Squibb Co (NYSE BMY) opened at $63.16 on Tuesday. The company has a market cap of $103,370.00, a PE ratio of 107.05, a price-to-earnings-growth ratio of 1.94 and a beta of 1.08. Bristol-Myers Squibb Co has a 1 year low of $51.56 and a 1 year high of $66.10. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.59 and a quick ratio of 1.46.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.67 by $0.01. The business had revenue of $5.45 billion for the quarter, compared to analysts’ expectations of $5.35 billion. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 33.68%. The business’s quarterly revenue was up 3.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.63 earnings per share. equities research analysts forecast that Bristol-Myers Squibb Co will post 3.22 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, February 1st. Stockholders of record on Friday, January 5th were given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 2.53%. The ex-dividend date of this dividend was Thursday, January 4th. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio is currently 271.19%.
In other news, Director Theodore R. Samuels II bought 4,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The shares were purchased at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the purchase, the director now owns 22,000 shares of the company’s stock, valued at $1,370,600. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the sale, the executive vice president now owns 584,373 shares in the company, valued at $37,031,717.01. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by corporate insiders.
Several equities analysts recently issued reports on BMY shares. Zacks Investment Research cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. Vetr lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $59.70 price target for the company. in a report on Thursday, December 28th. SunTrust Banks raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Monday, October 30th. BMO Capital Markets set a $49.00 price target on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Thursday, October 26th. Finally, Leerink Swann upped their target price on shares of Bristol-Myers Squibb from $61.00 to $72.00 and gave the stock an “outperform” rating in a report on Monday, October 23rd. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have assigned a buy rating to the company. Bristol-Myers Squibb has a consensus rating of “Hold” and an average target price of $65.58.
ILLEGAL ACTIVITY WARNING: “BB&T Securities LLC Increases Stake in Bristol-Myers Squibb Co (BMY)” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/13/bbt-securities-llc-has-35-95-million-position-in-bristol-myers-squibb-co-bmy.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.